VAMP8 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9 X = 4 bp deletion Frameshift = 99.7%.
ED B, Endobrevin, VAMP8_HUMAN, Vesicle-associated membrane protein 8
VAMP8 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9 X = 4 bp deletion Frameshift = 99.7%.
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
VAMP8 also known as synaptobrevin-like protein 2 or EDB is a SNARE protein with a mass of approximately 12 kDa. This protein is widely expressed in many tissues including the lung pancreas and kidney. It plays an important role in vesicle-mediated transport where it facilitates the fusion of vesicles with target membranes as part of a larger protein complex. By participating in these membrane fusion processes the protein contributes to cellular trafficking.
VAMP8 engages in vesicular transport mechanisms that support exocytosis and endocytosis processes. It forms part of the SNARE complex which is important for merging vesicles with their target compartments. Through this association VAMP8 aids the release of substances such as hormones and digestive enzymes from the cells. This process is critical for maintaining the balance and function of cellular activities across different tissues.
VAMP8 functions in the context of the trafficking pathways that include the endocytic and exocytic pathways. It is a participant in regulated exocytosis where it interacts with other SNARE proteins like syntaxin and SNAP-25 ensuring precise membrane fusion events occur. These pathways ensure proper cellular communication and debris clearance underlining the importance of VAMP8 in general cellular homeostasis.
VAMP8 is associated with conditions like inflammatory diseases and certain exocytic disorders. Researchers have observed its involvement in conditions like pancreatitis where its regulatory function in enzyme secretion becomes apparent. VAMP8 also has connections with other disease-related proteins such as those in the SNARE family which contribute to altered secretory pathways and inflammation. Understanding the precise mechanisms of VAMP8 helps in developing therapeutic approaches to managing these disorders.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Lane 1: Wild-type A431 cell lysate 20 ug
Lane 2: VAMP8 knockout A431 cell lysate 20 ug
Lane 3: THP-1 cell lysate 20 ug
Lane 4: SH-SY5Y (Human neuroblastoma cell line from bone marrow) whole cell lysate 20 ug
Lanes 1 - 4: Merged signal (red and green). Green - Anti-VAMP8/EDB antibody [EP2629Y] ab76021 observed at 13 kDa. Red - loading control, Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291 (Mouse anti-Alpha Tubulin [DM1A] observed at 55kDa.
Anti-VAMP8/EDB antibody [EP2629Y] ab76021 was shown to react with VAMP8/EDB in wild-type A-431 cells in western blot Loss of signal was observed when VAMP8 knockout cell line Human VAMP8 (EDB) knockout A-431 cell line ab269584 (knockout cell lysate ab270707) was used. Wild-type and VAMP8 knockout A-431 cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3% milk in TBS-T (0.1% Tween®) before incubation with Anti-VAMP8/EDB antibody [EP2629Y] ab76021 and Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291 (Mouse anti-Alpha Tubulin [DM1A] overnight at 4°C at a 1 in 10000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-VAMP8/EDB antibody [EP2629Y] (Anti-VAMP8/EDB antibody [EP2629Y] ab76021) at 1/10000 dilution
Lane 1: Wild-type A-431 (Human epidermoid carcinoma cell line) whole cell lysate at 20 µg
Lane 2: VAMP8 knockout A-431 (Human epidermoid carcinoma cell line) whole cell lysate at 20 µg
Lane 2: Western blot - Human VAMP8 (EDB) knockout A-431 cell line (Human VAMP8 (EDB) knockout A-431 cell line ab269584)
Lane 3: THP-1 (Human monocytic leukemia cell line) whole cell lysate at 20 µg
Lane 4: SH-SY5Y (Human neuroblastoma cell line from bone marrow) whole cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 11 kDa
Observed band size: 13 kDa
Knockout achieved by CRISPR/Cas9; X = 4 bp deletion; Frameshift = 99.7%
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com